CONMED Corporation 2015 Form 10-K Summary
Business Context and Reporting Period
CONMED is a medical technology company providing surgical devices and equipment for minimally invasive procedures in orthopedic surgery, general surgery and surgical visualization. The filing covers the fiscal year ended December 31, 2015; fourth-quarter data is included where relevant. The company had approximately 3,400 employees and sold products in more than 100 countries. International sales represented approximately 50% of 2015 revenue, and disposable products represented approximately 79% of revenue.
Financial Performance and Liquidity
| Metric | 2015 | 2014 | Change |
|---|---|---|---|
| Net sales | $719.2 million | $740.1 million | Down 2.8% |
| Gross profit | $381.7 million | $404.1 million | Down 5.5% |
| Gross margin | 53.1% | 54.6% | Down 1.5 points |
| Income from operations | $51.2 million | $52.8 million | Down 3.1% |
| Operating margin | 7.1% | 7.1% | Flat |
| Net income | $30.5 million | $32.2 million | Down 5.3% |
| Diluted EPS | $1.09 | $1.16 | Down 6.0% |
| Operating cash flow | $48.1 million | $65.2 million | Down 26.2% |
| Capital expenditures | $15.0 million | $15.4 million | Down 2.6% |
Fourth-quarter 2015 sales were $191.0 million, gross profit was $102.4 million, net income was $7.9 million and diluted EPS was $0.28, compared with fourth-quarter 2014 sales of $195.0 million, gross profit of $104.0 million, net income of $11.3 million and diluted EPS of $0.41.
At December 31, 2015, cash and equivalents were $72.5 million, total debt was $270.8 million, and shareholders’ equity was $585.1 million. Debt represented approximately 25% of total capitalization. The company had $179.3 million of available borrowing capacity under its $450.0 million revolving facility, subject to approximately $5.1 million of letters of credit, and was in compliance with its debt covenants.
Working capital was $287.8 million. Cash flow declined principally because of a $34.5 million increase in inventories, higher restructuring payments and increased accounts receivable. Financing cash outflows included $22.1 million of dividends, $16.7 million of payments under the MTF distribution agreement and $3.9 million of contingent consideration payments. No shares were repurchased during 2015.
Material Changes Versus the Prior Comparable Period
- Sales declined across all product lines: orthopedic surgery decreased 3.4% to $389.0 million, general surgery decreased 1.8% to $274.2 million, and surgical visualization decreased 3.3% to $56.0 million.
- Reported sales were adversely affected by foreign currency. In local currency, excluding hedging effects, sales increased 0.3%; foreign exchange reduced sales by approximately $23.0 million and pretax income by approximately $8.2 million.
- Capital equipment sales increased 3.8% to $151.9 million, while single-use product sales decreased 4.5% to $567.3 million.
- Gross margin contracted primarily because of unfavorable foreign exchange effects and higher operational restructuring costs.
- Selling and administrative expense fell $20.4 million, partly because 2014 included $12.5 million of executive management restructuring costs, as well as shareholder activism and legal costs.
- Restructuring and other expense totaled $24.2 million in 2015, including $8.0 million of facility consolidation costs and $13.7 million of administrative restructuring costs. The comparable 2014 total was $29.6 million.
- Inventory increased to $166.9 million from $148.1 million, partly due to the consolidation of the Centennial, Colorado facility, salesforce evaluation inventory and lower-than-expected fourth-quarter video sales.
- The effective tax rate increased to 32.4% from 31.0%, including a $1.1 million tax charge associated with repatriation of foreign earnings.
Guidance, Outlook, Risks and Unusual Items
- On January 4, 2016, CONMED acquired SurgiQuest for $265 million in cash. SurgiQuest’s AirSeal system is expected by management to generate approximately $55 million to $60 million of 2016 revenue.
- The acquisition was financed through a new $175.0 million term loan and a $525.0 million revolving credit facility, increasing post-year-end leverage and financing obligations.
- Management expected $3.5 million to $4.5 million of annual cost-of-sales savings from the Centennial consolidation, with full realization expected in 2016. Capital expenditures were expected to be $15 million to $20 million in 2016.
- The company planned to continue evaluating operational and administrative restructuring; additional costs were expected, but the filing did not provide a clear estimate.
- CONMED remains subject to FDA and foreign regulatory oversight. Its Centennial facility previously received a Form 483, a 2014 FDA Warning Letter and subsequent repeat observations. Remediation costs had not been material, but additional regulatory actions, fines, consent decrees or product disruptions remain possible.
- Key risks include foreign currency exposure, competitive pricing pressure, healthcare cost containment, regulatory compliance, product recalls and liability, supplier or raw-material disruption, patent litigation, allograft tissue availability, cybersecurity and acquisition integration.
- Approximately $65.9 million of year-end cash was held by foreign subsidiaries with unremitted earnings that management intended to permanently reinvest. Repatriation could create additional taxes.
- Variable-rate debt created interest-rate exposure: a 1% increase in applicable market rates was estimated to increase annual interest expense and reduce pretax income by approximately $2.7 million.
Important Facts for Investors to Verify
- Verify the final purchase-price allocation, integration progress, revenue contribution and profitability of SurgiQuest.
- Monitor whether the projected $3.5 million to $4.5 million restructuring savings are realized and whether additional restructuring charges are incurred.
- Assess inventory normalization and the effect of inventory growth on operating cash flow.
- Review debt balances, covenant headroom, interest rates and leverage after the January 2016 refinancing and acquisition.
- Track FDA remediation at the Centennial facility and any subsequent inspections, warning letters, recalls or enforcement actions.
- Evaluate the sustainability of revenue and margins after foreign-exchange effects, particularly in the orthopedic and single-use product businesses.
- Confirm the availability and regulatory status of sports medicine allograft tissue supplied through the Musculoskeletal Transplant Foundation.